Our Team

Amanda Feilding


Amanda Feilding has been called the ‘hidden hand’ behind the renaissance of psychedelic science, and her contribution to global drug policy reform has also been pivotal and widely acknowledged. Amanda was first introduced to LSD in the mid-1960s, at the height of the first wave of scientific research into psychedelics. Impressed by its capacity to initiate mystical states of consciousness and heighten creativity, she quickly recognized its transformative and therapeutic power. Inspired by her experiences, she began studying the mechanisms underlying the effects of psychedelic substances and dedicated herself to exploring ways of harnessing their potential to cure sickness and enhance well-being.

In 1996, Amanda set upThe Foundation to Further Consciousness, changing its name to theBeckley Foundationin 1998. She realized that the potential harms and benefits of cannabis and psychedelics could only be adequately assessed by developing a sound scientific understanding of their mechanisms of action. Through the Foundation, she set about using cutting-edge brain imaging technologies to examine the neurophysiological changes underlying altered states of consciousness.

Her long-held aim is to further our understanding of consciousness and how changes in cerebral circulation and neuronal activity underlie the effects of various psychoactive substances so that we can better harness their potential to improve the human condition.

Having watched the development of the ‘War on Drugs’ with dismay, Amanda felt compelled to do whatever she could to draw attention to its devastating and unintended consequences. Bringing together a network of leading international scientists, politicians, and drug policy analysts, she was among the first to begin creating a scientific evidence base to help reform global drug policies, in order to better protect health, reduce harms and economic costs, and uphold human rights.

From 1998, she initiated and hosted a series of eleven international seminars at theHouse of Lords, discussing key policy issues and drawing attention to the ignored topics of cannabis and psychedelics. These seminars, and the reports arising from them, were highly influential in changing attitudes among thinkers and policy-makers worldwide.Through the Beckley Foundation’s Policy Programme, Amanda has commissioned and published over 40 books, reports, and policy papers that have analyzed the negative consequences of the criminalization of drug use, and laid out possible alternatives which could protect public health, diminish violence and governmental costs, and protect human rights. Over the years, her advice has been sought by presidents and governments, and in 2011, she wrote an influential public letter calling for drug policy reform, which was signed by presidents, Nobel laureates, and other notables

Through her leadership of theBeckley Foundation’s Science Programme, Amanda has initiated much ground-breaking research and has co-authored over 80 scientific articles published in peer-reviewed journals. She collaborates with leading scientists and institutions around the world to design and direct a wide range of scientific research projects (including clinical trials) investigating the effects of psychoactive substances on brain function, subjective experience, and clinical symptoms, with a focus on cannabis, the psychedelics (LSD, psilocybin, ayahuasca, DMT, 5-MEO-DMT) and MDMA. This pioneering research has not only shed light on the mechanisms of action and therapeutic potential of these substances, but also on consciousness itself. This has led to a groundswell of interest in, and recognition of, the possible benefits that careful use of these extraordinary compounds can bring. The research that Amanda has initiated has shown that psychedelics hold great promise in helping individuals with illnesses such as treatment-resistant depression and addiction.

Furthermore, in her role as co-director of the Beckley/Imperial Research Programme, she helped generate the world’s first images of the brain on LSD, one of her long-standing ambitions.While her first love is science, Amanda continues to bridge the divide between science and drug policy: her pioneering psychedelic research is providing the scientific evidence to fuel a fair debate on drug policy reform. Such reform will, in turn, allow for research on currently prohibited psychedelic substances to flourish, uninhibited by regulatory obstructions. Ultimately, the goal of Amanda’s work is to make psychedelics and cannabis into approved medicines, so that they can be legally prescribed at clinics for those in need.

Mike Trace

Mike Trace has a wide range of experience in the field of drug treatment and policy, from direct work with problem drug users to senior positions in national government and international agencies.

Following a period of 12 years working in and managing projects that provided treatment to the homeless, drug users, and offenders, Mike was offered the post of Deputy UK Anti-Drug Co-ordinator (National Drug Czar) in 1997 and held this post until 2002. His duties included the creation of the UK National Drug Strategy–Tackling Drugs To Build A Better Britain – and the oversight of the first 4 years of its implementation.


From 2000 to 2003, he was the Chairman of the European Union drugs agency, the European Monitoring Centre on Drugs and Drug Addiction (EMCDDA).


From January to November 2002, Mike held the post of Director of Performance at the UK National Treatment Agency, set up by the UK government to oversee the rapid expansion of the drug-dependence treatment sector. In November 2002, he left to take up the post of Chief, of the Demand Reduction Section at the United Nations Office on Drugs and Crime in Vienna.

Since leaving his United Nations post, Mike has returned to the UK and the non-governmental sector. He currently combines two leadership roles in the field of drug policy and drug dependence treatment:

– as Chief Executive of The Forward Trust

– as Chairman of the International Drug Policy Consortium